Affordable Access

Publisher Website

Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.

  • Skouras, Stavros1
  • Torner, Jordi2
  • Andersson, Patrik3
  • Koush, Yury4
  • Falcon, Carles1, 5, 6
  • Minguillon, Carolina1, 6, 7
  • Fauria, Karine1, 7
  • Alpiste, Francesc2
  • Blenow, Kaj8, 9
  • Zetterberg, Henrik8, 9, 10, 11
  • Gispert, Juan D1, 5, 6, 12
  • Molinuevo, José L1, 6, 7, 12
  • 1 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. , (Spain)
  • 2 BarcelonaTech, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain. , (Spain)
  • 3 SUBIC, Stockholm University, Stockholm, Sweden. , (Sweden)
  • 4 Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
  • 5 Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. , (Spain)
  • 6 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. , (Spain)
  • 7 CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. , (Spain)
  • 8 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. , (Sweden)
  • 9 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. , (Sweden)
  • 10 Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
  • 11 UK Dementia Research Institute at UCL, University College London, London, UK.
  • 12 Universitat Pompeu Fabra, Barcelona, Spain. , (Spain)
Published Article
Oxford University Press
Publication Date
Mar 01, 2020
DOI: 10.1093/brain/awaa011
PMID: 32091109


Research into hippocampal self-regulation abilities may help determine the clinical significance of hippocampal hyperactivity throughout the pathophysiological continuum of Alzheimer's disease. In this study, we aimed to identify the effects of amyloid-β peptide 42 (amyloid-β42) and phosphorylated tau on the patterns of functional connectomics involved in hippocampal downregulation. We identified 48 cognitively unimpaired participants (22 with elevated CSF amyloid-β peptide 42 levels, 15 with elevated CSF phosphorylated tau levels, mean age of 62.705 ± 4.628 years), from the population-based 'Alzheimer's and Families' study, with baseline MRI, CSF biomarkers, APOE genotyping and neuropsychological evaluation. We developed a closed-loop, real-time functional MRI neurofeedback task with virtual reality and tailored it for training downregulation of hippocampal subfield cornu ammonis 1 (CA1). Neurofeedback performance score, cognitive reserve score, hippocampal volume, number of apolipoprotein ε4 alleles and sex were controlled for as confounds in all cross-sectional analyses. First, using voxel-wise multiple regression analysis and controlling for CSF biomarkers, we identified the effect of healthy ageing on eigenvector centrality, a measure of each voxel's overall influence based on iterative whole-brain connectomics, during hippocampal CA1 downregulation. Then, controlling for age, we identified the effects of abnormal CSF amyloid-β42 and phosphorylated tau levels on eigenvector centrality during hippocampal CA1 downregulation. Across subjects, our main findings during hippocampal downregulation were: (i) in the absence of abnormal biomarkers, age correlated with eigenvector centrality negatively in the insula and midcingulate cortex, and positively in the inferior temporal gyrus; (ii) abnormal CSF amyloid-β42 (<1098) correlated negatively with eigenvector centrality in the anterior cingulate cortex and primary motor cortex; and (iii) abnormal CSF phosphorylated tau levels (>19.2) correlated with eigenvector centrality positively in the ventral striatum, anterior cingulate and somatosensory cortex, and negatively in the precuneus and orbitofrontal cortex. During resting state functional MRI, similar eigenvector centrality patterns in the cingulate had previously been associated to CSF biomarkers in mild cognitive impairment and dementia patients. Using the developed closed-loop paradigm, we observed such patterns, which are characteristic of advanced disease stages, during a much earlier presymptomatic phase. In the absence of CSF biomarkers, our non-invasive, interactive, adaptive and gamified neuroimaging procedure may provide important information for clinical prognosis and monitoring of therapeutic efficacy. We have released the developed paradigm and analysis pipeline as open-source software to facilitate replication studies. © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Report this publication


Seen <100 times